Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study.

IF 4.9 4区 医学 Q1 PARASITOLOGY
Pathogens and Global Health Pub Date : 2024-05-01 Epub Date: 2023-07-31 DOI:10.1080/20477724.2023.2240088
María Asunción Pérez-Jacoiste Asín, Marta De Castro, Begoña De Dios, Ana Pérez-Ayala, Antonio Lalueza, Ana García-Reyne, Irene Losada, Juan María Herrero-Martínez, Pilar Hernández Jiménez, Carlos Lumbreras, Manuel Lizasoain, Francisco López Medrano
{"title":"Enhancing screening adherence for strongyloides infection in latinx inpatients with COVID-19: a local protocol implementation study.","authors":"María Asunción Pérez-Jacoiste Asín, Marta De Castro, Begoña De Dios, Ana Pérez-Ayala, Antonio Lalueza, Ana García-Reyne, Irene Losada, Juan María Herrero-Martínez, Pilar Hernández Jiménez, Carlos Lumbreras, Manuel Lizasoain, Francisco López Medrano","doi":"10.1080/20477724.2023.2240088","DOIUrl":null,"url":null,"abstract":"<p><p><i>Strongyloides stercoralis</i> hyperinfection syndrome has been observed in immunosuppressed coronavirus disease 2019 (COVID-19) patients. Detecting and treating asymptomatic <i>Strongyloides</i> infection in individuals from endemic areas can effectively prevent hyperinfection. Unfortunately, many clinicians are unaware of this neglected infection. Therefore, we aimed to evaluate whether including <i>Strongyloides</i> screening in COVID-19 management protocols would encourage this practice. To accomplish this, we conducted a retrospective single-center study at 'Hospital Universitario 12 de Octubre' in Madrid, Spain, comparing two consecutive cohorts. The first cohort comprised all Latinx patients over 18 years old who were admitted for COVID-19 between March 1<sup>st</sup> and April 30<sup>th</sup>, 2020. The second cohort consisted of Latinx patients admitted between July 1<sup>st</sup> and December 31<sup>st</sup>, 2020, following an amendment to the COVID-19 management protocol that recommended screening for strongyloidiasis in at-risk patients. We identified 559 and 795 patients in the first and second periods, respectively. The percentage of individuals screened increased significantly from 8.8% to 51.6% after the screening recommendation was included in the protocol (odds ratio [OR] 11.08, 95% confidence interval [CI] 8.01-15.33). In both periods, the screening rate was significantly higher among those receiving immunosuppression than those who did not receive steroids and/or tocilizumab. No other factors influenced the screening rate. In conclusion, including strongyloidiasis screening recommendations in COVID-19 management protocols led to its increased implementation. However, the overall screening rate remained low, emphasizing the need for further efforts to enhance screening practices.</p>","PeriodicalId":19850,"journal":{"name":"Pathogens and Global Health","volume":" ","pages":"232-240"},"PeriodicalIF":4.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11221480/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathogens and Global Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/20477724.2023.2240088","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/31 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Strongyloides stercoralis hyperinfection syndrome has been observed in immunosuppressed coronavirus disease 2019 (COVID-19) patients. Detecting and treating asymptomatic Strongyloides infection in individuals from endemic areas can effectively prevent hyperinfection. Unfortunately, many clinicians are unaware of this neglected infection. Therefore, we aimed to evaluate whether including Strongyloides screening in COVID-19 management protocols would encourage this practice. To accomplish this, we conducted a retrospective single-center study at 'Hospital Universitario 12 de Octubre' in Madrid, Spain, comparing two consecutive cohorts. The first cohort comprised all Latinx patients over 18 years old who were admitted for COVID-19 between March 1st and April 30th, 2020. The second cohort consisted of Latinx patients admitted between July 1st and December 31st, 2020, following an amendment to the COVID-19 management protocol that recommended screening for strongyloidiasis in at-risk patients. We identified 559 and 795 patients in the first and second periods, respectively. The percentage of individuals screened increased significantly from 8.8% to 51.6% after the screening recommendation was included in the protocol (odds ratio [OR] 11.08, 95% confidence interval [CI] 8.01-15.33). In both periods, the screening rate was significantly higher among those receiving immunosuppression than those who did not receive steroids and/or tocilizumab. No other factors influenced the screening rate. In conclusion, including strongyloidiasis screening recommendations in COVID-19 management protocols led to its increased implementation. However, the overall screening rate remained low, emphasizing the need for further efforts to enhance screening practices.

通过 COVID-19 提高拉丁裔住院患者对强直性脊柱炎感染筛查的依从性:一项地方协议实施研究。
在免疫抑制的 2019 年冠状病毒病(COVID-19)患者中观察到了盘尾丝虫高感染综合征。检测和治疗来自流行地区的无症状盘尾丝虫感染可有效预防高感染。遗憾的是,许多临床医生并不了解这种被忽视的感染。因此,我们旨在评估将斯龙线虫筛查纳入 COVID-19 管理方案是否会鼓励这种做法。为此,我们在西班牙马德里的十月十二日大学医院(Hospital Universitario 12 de Octubre)进行了一项回顾性单中心研究,比较了两个连续的队列。第一个队列包括 2020 年 3 月 1 日至 4 月 30 日期间因 COVID-19 入院的所有 18 岁以上拉丁裔患者。第二个队列包括 2020 年 7 月 1 日至 12 月 31 日期间因 COVID-19 管理方案修订建议对高危患者进行强直性脊柱炎筛查而入院的拉丁裔患者。我们在第一阶段和第二阶段分别发现了 559 名和 795 名患者。将筛查建议纳入方案后,筛查比例从 8.8% 显著增加到 51.6%(几率比 [OR] 11.08,95% 置信区间 [CI] 8.01-15.33)。在这两个时期,接受免疫抑制的患者的筛查率明显高于未接受类固醇和/或托珠单抗治疗的患者。没有其他因素影响筛查率。总之,将强直性脊柱炎筛查建议纳入COVID-19管理方案后,其实施率有所提高。然而,总体筛查率仍然很低,这强调了进一步加强筛查工作的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pathogens and Global Health
Pathogens and Global Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-PARASITOLOGY
CiteScore
6.00
自引率
0.00%
发文量
60
审稿时长
6-12 weeks
期刊介绍: Pathogens and Global Health is a journal of infectious disease and public health that focuses on the translation of molecular, immunological, genomics and epidemiological knowledge into control measures for global health threat. The journal publishes original innovative research papers, reviews articles and interviews policy makers and opinion leaders on health subjects of international relevance. It provides a forum for scientific, ethical and political discussion of new innovative solutions for controlling and eradicating infectious diseases, with particular emphasis on those diseases affecting the poorest regions of the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信